Levaquin (FQAD) Fluoroquinolone Associated Disability Lawsuit

fluoroquinolone disability
Levaquin and similar antibiotics may be associated with a condition called fluoroquinolone-associated disability, or FQAD. In November 2015, two U.S. Food & Drug Administration (FDA) advisory committees heard testimony from a number of fluoroquinolone patients who developed symptoms that may be associated with FQAD, prompting the members to recommend new warnings for the drug’s labels.

Filing a Levaquin Lawsuit Can Help

Alleged victims of FQAD may be entitled to compensation for their medical bills, lost wages, pain and suffering, and more. If you would like to learn more about filing a Levaquin FQAD lawsuit, please contact the nationwide law firm of Bernstein Liebhard LLP at (888) 994-5118.

What is FQAD?

FQAD is the term for a “constellation of symptoms” reported among some patients treated with Levaquin, Cipro, Avelox and other fluoroquinolone antibiotics. These symptoms may include:

Cardiovascular Symptoms:

  • Cardiac Arrhythmia
  • QT Prolongation
  • Torsades de Pointes

Musculoskeletal Symptoms

  • Tendon Rupture
  • Tendinitis

Symptoms of the Nervous System

  • Abnormal Sensations in Arms Hands Legs or Feet
  • Abnormal sensitivity to touch, heat, cold, etc.
  • Abnormal vibratory sense with an extremity
  • Muscle weakness in arms, hands, legs or feet
  • Numbness in arms, hands, legs or feet
  • Pain in arms, hands, legs or feet
  • Paralysis
  • Prickling sensation in arms, hands, legs or feet
  • Permanent nerve damage in arms, hands, legs or feet

Neuropsychiatric Symptoms

  • Anxiety
  • Cognitive impairment
  • Confusion
  • Delusional behavior
  • Depression
  • Dizziness
  • Visual and/or auditory hallucinations
  • Intracranial Pressure
  • Neurosis
  • Nightmares
  • Paranoia
  • Psychosis
  • Pseudotumor cerebri
  • Seizures
  • Suicidal Thoughts
  • Tremors
  • Trouble Sleeping

Sensory Symptoms

  • Hearing loss
  • Worsening of Myasthenia Gravis
  • Vision loss
  • Severe photosensitivity/phototoxicity reactions (burning, erythema, exudation, vesicles, blistering or edema)

Skin Abnormalities

  • Lack of or increased sweating

FDA Orders Stronger Warnings for Fluoroquinolone Antibiotics Following Advisory Panel Review

In November 2015, the FDA convened a joint meeting of its Antimicrobial Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee, and asked the members to examine the use of fluoroquinolones in treating acute bacterial sinusitis, acute bacterial exacerbation of chronic bronchitis in patients with COPD, or uncomplicated urinary tract infections. During the meeting, the FDA advisors heard testimony from patients who had developed FQAD symptoms while using Levaquin and other fluoroquinolones. The Committees ultimately concluded that the current labeling for these drugs was unacceptable, and overwhelmingly endorsed the inclusion of stronger warnings. Read More

The following May,  the FDA ordered fluoroquinolone manufacturers to update their products’ boxed warnings, after the agency concluded that the drugs are generally too dangerous for patients with sinusitis, bronchitis and uncomplicated urinary tract infections who have other treatment options. Complications that may be associated with the antibiotics include potentially permanent complications involving the tendons, muscles, joints, nerves and central nervous system that can occur together. Read More


Legal Help for Alleged Victims of FQAD

Bernstein Liebhard LLP is investigating legal claims on behalf of individuals who may have developed FQAD related to the use of Levaquin, Cipro or Avelox. Please contact our Firm if you or a loved one were healthy prior to beginning fluoroquinolone therapy, and went on to experience any of the above symptoms for 30 days or longer after treatment ended. To arrange for your free, no-obligation review of your case, please call (888) 994-5118.

  1. FDA (2015) “ FDA Briefing Document – Joint meeting of its Antimicrobial Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee” http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Anti-InfectiveDrugsAdvisoryCommittee/UCM467383.pdf
  2. FDA (2015) – “Joint meeting of its Antimicrobial Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee” http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Anti-InfectiveDrugsAdvisoryCommittee/UCM477657.pdf
Last Modified: May 20, 2016

Get the latest news and litigation updates about this case by following us on Facebook. Click the "Like" button below.


Follow Us

RXInjuryHelp.com on Google+  RXInjuryHelp.com on Facebook  RXInjuryHelp.com on LinkedIn  RXInjuryHelp.com on Twitter  RXInjuryHelp.com on YouTube  RXInjuryHelp.com on Pinterest

Skip to content